Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
January 26, 2009
- Sato Enters the Field of Diagnostic Agents
January 26, 2009
- Nichi-Iko Aims at Entering Global Top-10 Club in 2012: President Tamura
January 26, 2009
- 3,030 Reports on Device Malfunctions Received in 1st Half of FY2008
January 26, 2009
- JGA to Demand Fixed Sum Price Adjustment Range for Low-Priced Generics
January 26, 2009
- Kaken: Hand-Sized Seprafilm
January 26, 2009
- Cravit to See NHI Price Listing for 41 Generics from 32 Companies
January 26, 2009
- Endometrial Ablation Using Microwaves Approved as Advanced Therapy
January 26, 2009
- Generics Account for 18% of Drug Cost at a Yokohama Hospital
January 26, 2009
- SELF-MEDICATION NEWS IN BRIEF
January 26, 2009
- Review of Febuxostat by FDA to Be Extended
January 26, 2009
- Revised Version of Hypertension Treatment GL Issued
January 26, 2009
- 2 Anti-HIV Drugs Included in NHI Drug Price List
January 26, 2009
- Draft GL on Peritoneal Dialysis Published: JSDT
January 26, 2009
- NHI Prices of Novoseven Re-Priced Upward due to Unprofitability
January 26, 2009
- Series of Tamiflu-Resistant Viruses Detected
January 26, 2009
- JPMA Creates Project Team to Promote Development of Unapproved Drugs, Indications
January 26, 2009
- Medical Fees Grew 2.2% in 1st Half of FY2008
January 26, 2009
- JPO Considers Extension of Patent Periods for DDS Formulations
January 26, 2009
- Total Fee Points Up 0.7% at Psychiatric Hospitals
January 26, 2009
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…